Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H. Strickler, Thierry André, Kimmie Ng et al.|The Lancet Oncology|2023Cited by 244
Fracturing-flooding technology for low permeability reservoirs: A reviewNianyin Li, Chen Jiang, Shijie Zhu et al.|Petroleum|2023Cited by 49